论文部分内容阅读
目的探讨淋系抗原在急性髓系白血病细胞上的表达及意义。方法采用间接免疫荧光法检测182例急性髓系白血病细胞的免疫表型。根据FAB亚型和免疫标志将病例分为2组:伴淋系相关抗原的急性髓细胞性白血病(Ly+AML),不伴淋系相关抗原的急性髓细胞性白血病(Ly-AML)。结果182例AML中有64例表达淋系抗原(33%),CD+7在AML中表达率为54.7%,M0中阳性率最高100%,M1次之78%。Ly+AML组的白细胞、血小板数高于Ly-AML,有显著性差异。Ly+AML组与Ly-AML组的诱导缓解率及临床特征无显著性差异。Ly+AML组和Ly-AML组比较,平均缓解期较短。结论CD+7AML与AML蛳M0、M1有着密切的关系,可以看作是一个独特的临床亚型。Ly+AML较之Ly-AML具有不同的临床特征和短CR期。Ly+AML的出现可以作为危险因子中的一个因子来选择更合适的化疗也许是必要的。
Objective To investigate the expression of lymphoid antigen in acute myeloid leukemia cells and its significance. Methods The immunophenotypes of 182 acute myeloid leukemia cells were detected by indirect immunofluorescence. The cases were divided into two groups according to FAB subtypes and immunodeficiency markers: Lymphomyelitis-associated AML, Ly-AML without lymphoid-associated antigen. Results In 182 AML cases, 64 cases expressed lymphoid antigen (33%). The positive rate of CD + 7 in AML was 54.7%. The positive rate was 100% in M0 and 78% in M1. The number of white blood cells and platelets in Ly + AML group was significantly higher than that in Ly-AML group. There was no significant difference in induction remission rate and clinical features between Ly + AML group and Ly-AML group. The average remission period was shorter in Ly + AML group and Ly-AML group. Conclusion CD + 7 AML is closely related to AML 蛳 M0, M1 and can be regarded as a unique clinical subtype. Ly + AML has different clinical features and shorter CR period than Ly-AML. The emergence of Ly + AML may be necessary as a factor in risk factors to choose more appropriate chemotherapy.